Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel

Cancer

Volumn 115, Issue 11, 2009, Pages 2453-2463

  Su, Dan ^a   Smith, Stephanie M ^b   Preti, Mario ^b   Schwartz, Peter ^c   Rutherford, Thomas J ^c   Menato, Guido ^b   Danese, Saverio ^d   Ma, Shenglin ^a   Yu, Herbert ^b   Katsaros, Dionyssios ^b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b YALE CANCER CENTER   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d Sant'Anna Hospital   (Italy)

Author keywords

Chemotherapy; Ovarian cancer; Prognosis; Stathmin; Tubulin

Indexed keywords

BETA III TUBULIN; BETA TUBULIN; CISPLATIN; CYCLOPHOSPHAMIDE; MESSENGER RNA; PACLITAXEL; STATHMIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTINUOUS INFUSION; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; POSTOPERATIVE PERIOD; STATHMIN; SURVIVAL ANALYSIS; TUBULIN;

EID: 66649102458     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24282     Document Type: Article

References (47)

1. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 2006;33(2 suppl 6): S3-S11. (Pubitemid 43729194)
2. du Bois A, Luck HJ, Meier W, et al. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynakologische Onkologie. Semin Oncol. 1997;24(4 suppl 11):S11-28-S11-33.
3. Aravantinos G, Fountzilas G, Kosmidis P, et al. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol. 2005;16:1116-1122. (Pubitemid 41418314)
4. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14:1291-1295.
5. Naniwa J, Kigawa J, Kanamori Y, et al. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:76-82. (Pubitemid 46213973)
6. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 Single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res. 2006;12:854-859. (Pubitemid 43259868)
7. Cassinelli G, Supino R, Perego P, et al. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer. 2001;92:738-747. (Pubitemid 32385719)
8. Zhou J, O'Brate A, Zelnak A, Giannakakou P. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol. Cancer Res. 2004;64:8708-8714. (Pubitemid 39552087)
9. Kamath K, Wilson L, Cabral F, Jordan MA. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem. 2005;280:12902-12907. (Pubitemid 40491112)
10. Martello LA, Verdier-Pinard P, Shen HJ, et al. Elevated levels of microtubule destabilizing factors in a taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res. 2003;63:1207-1213. (Pubitemid 36355832)
11. Hwang IG, Ahn MJ, Park BB, et al. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer. 2008;113:1379-1386.
12. Olaussen KA, Dunant A, Fouret P, et al. DNA Repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-991. (Pubitemid 44343542)
13. Smith S, Su D, Rigault de la Longrais IA, et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol. 2007;25:5172-5179. (Pubitemid 350232247)
14. Jourdain I, Lachkar S, Charbaut E, et al. A synergistic relationship between 3 regions of stathmin family proteins is required for the formation of a stable complex with tubulin. Biochem J. 2004;378:877-888. (Pubitemid 38406865)
15. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994;5(suppl 6):S3-S6.
16. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E. The binding conformation of taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A. 2001;98:5312-5316. (Pubitemid 32397125)
17. Nicoletti MI, Valoti G, Giannakakou P, et al. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Clin Cancer Res. 2001;7:2912-2922. (Pubitemid 32911402)
18. Ferrandina G, Zannoni GF, Martinelli E, et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res. 2006;12:2774-2779. (Pubitemid 43752116)
19. Balachandran R, Welsh MJ, Day BW. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene. 2003;22:8924-8930. (Pubitemid 38021508)
20. Yuan RH, Jeng YM, Chen HL, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006;209:549-558. (Pubitemid 44194570)
21. Kouzu Y, Uzawa K, Koike H, et al. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer. 2006;94:717-723. (Pubitemid 43361904)
22. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol. 1989;96:889-892.
23. Scully RE, Sobin LH. Histologic typing of ovarian tumors. Arch Pathol Lab Med. 1987;111:794-795. (Pubitemid 17121985)
24. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214. (Pubitemid 11167383)
25. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group study. Ann Oncol. 1996;7:361-364. (Pubitemid 26246787)
26. Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 2002;62:6864-6869. (Pubitemid 35424074)
27. George SL. Response rate as an endpoint in clinical trials. J Natl Cancer Inst. 2007;99:98-99.
28. Pazdur R. Response rates, survival, and chemotherapy trials. J Natl Cancer Inst. 2000;92:1552-1553.
29. Jourdain L, Curmi P, Sobel A, et al. Stathmin: a tubulinsequestering protein which forms a ternary T2S complex with 2 tubulin molecules. Biochemistry. 1997;36:10817-10821. (Pubitemid 27396235)
30. Liang XJ, Choi Y, Sackett DL, Park JK. Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells. Cancer Res. 2008;68:5267-5272.
31. Yoshie M, Kashima H, Bessho T, Takeichi M, Isaka K, Tamura K. Expression of stathmin, a microtubule regulatory protein, is associated with the migration and differentiation of cultured early trophoblasts. Hum Reprod. 2008;23:2766-2774.
32. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene. 2007;26:1003-1012. (Pubitemid 46272214)
33. Mistry SJ, Atweh GF. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mol Cancer Ther. 2006;5:3248-3257. (Pubitemid 46092068)
34. Mistry SJ, Bank A, Atweh GF. Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure. Mol Cancer Res. 2007;5:773-782. (Pubitemid 47294805)
35. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer. 2000;83:311-318. (Pubitemid 30453569)
36. Chen G, Wang H, Gharib TG, et al. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics. 2003;2:107-116.
37. Urano N, Fujiwara Y, Doki Y, et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol. 2006;28:375-381.
38. Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol. 2005;16(suppl 4):iv14-iv19. (Pubitemid 43084940)
39. Seve P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res. 2007;13:994-999. (Pubitemid 46340378)
40. Ferrandina G, Martinelli E, Zannoni GF, et al. Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome. Gynecol Oncol. 2007;104:326-330. (Pubitemid 46135663)
41. Tommasi S, Mangia A, Lacalamita R, et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of betatubulins. Int J Cancer. 2007;120:2078-2085. (Pubitemid 46555844)
42. Dumontet C, Isaac S, Souquet PJ, et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy [serial online]. Bull Cancer. 2005;92:E25-E30.
43. Seve P, Mackey J, Isaac S, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther. 2005;4:2001-2007. (Pubitemid 43056983)
44. Mozzetti S, Ferlini C, Concolino P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res. 2005;11:298-305. (Pubitemid 40075808)
45. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton. 2003;56:45-56. (Pubitemid 37059485)
46. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer. 1998;77:562-566. (Pubitemid 28059462)
47. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997;100:1282-1293. (Pubitemid 27386315)